

**REMARKS**

**Claim status.** Claims 17 to 25, 39 to 42, and 62 to 66 are now in the case. Claims 17, 21 and 22 are currently amended to address the matters raised in the office action mailed December 30, 2003. Claim 66 is added.

**Support for amendments.** No new matter is added by the current amendments to the specification and claims.

The new Sequence Listing and associated specification amendments merely correct errors in the previous Sequence Listing. The Examiner stated that SEQ ID NOS: 123 and 125 were the same as SEQ ID NOS: 171 and 173, respectively. The Applicants reviewed the sequences and noted that the sequences in the Sequence Listing were different, but those of the associated figures were the same. Upon further review of the Sequence Listing, the Applicants noted further duplication in the Sequence Listing and made appropriate amendments. All of the sequences currently in the Sequence Listing are in the specification as previously filed, so no new matter is added by the amendment to the Sequence Listing or the corresponding amendments to the specification.

The sequences identified as SEQ ID NOS: 171, 172 and 173 were erroneously duplicative of SEQ ID NOS: 121, 123 and 125 and removed by amendment for that reason.

Claim 66 is supported in the specification at page 28, line 15; page 28, line 32; and page 74, line 20.

The remaining amendments address formal matters and are clearly supported in the specification as filed.

**Conclusion.** In light of the foregoing amendments and remarks, the Applicants respectfully request entry of all amendments, withdrawal of all objections and rejections, and allowance of all claims.

Respectfully submitted,



Timothy J. Gadi  
Attorney for Applicants  
Registration No.: 33,111  
Phone: (805) 447-2688  
Date: 04/05/04

Please send all future correspondence to:  
US Patent Operations/ TJG  
Dept. 4300, M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1799